PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,494,156 | -39.4% | 509,242 | +0.4% | 0.00% | 0.0% |
| Q2 2023 | $14,014,573 | +530.5% | 507,407 | +425.0% | 0.00% | – |
| Q1 2023 | $2,222,714 | +197.3% | 96,640 | +41.0% | 0.00% | – |
| Q4 2022 | $747,617 | -96.8% | 68,526 | -97.6% | 0.00% | -100.0% |
| Q3 2022 | $23,679,000 | -14.2% | 2,808,808 | -19.5% | 0.00% | -33.3% |
| Q2 2022 | $27,613,000 | -83.6% | 3,491,006 | -51.0% | 0.00% | -76.9% |
| Q1 2022 | $168,805,000 | -27.9% | 7,128,579 | +4.1% | 0.01% | -23.5% |
| Q4 2021 | $234,177,000 | +103.5% | 6,847,277 | +5.5% | 0.02% | +88.9% |
| Q3 2021 | $115,049,000 | -64.0% | 6,492,638 | -8.8% | 0.01% | -64.0% |
| Q2 2021 | $319,383,000 | +87.7% | 7,116,383 | +8.3% | 0.02% | +66.7% |
| Q1 2021 | $170,195,000 | +30.8% | 6,571,227 | +1.8% | 0.02% | +25.0% |
| Q4 2020 | $130,087,000 | +27.9% | 6,452,764 | +24.1% | 0.01% | +20.0% |
| Q3 2020 | $101,682,000 | +11.5% | 5,201,081 | +0.7% | 0.01% | 0.0% |
| Q2 2020 | $91,217,000 | +215.6% | 5,165,205 | +26.2% | 0.01% | +150.0% |
| Q1 2020 | $28,905,000 | +0.5% | 4,094,144 | +0.3% | 0.00% | +33.3% |
| Q4 2019 | $28,771,000 | -39.2% | 4,080,967 | +3.5% | 0.00% | -50.0% |
| Q3 2019 | $47,344,000 | +11.4% | 3,942,012 | +12.3% | 0.01% | +20.0% |
| Q2 2019 | $42,499,000 | -6.3% | 3,509,404 | -2.7% | 0.01% | 0.0% |
| Q1 2019 | $45,343,000 | +85.7% | 3,607,249 | -0.6% | 0.01% | +66.7% |
| Q4 2018 | $24,416,000 | -31.4% | 3,627,902 | +4.9% | 0.00% | -25.0% |
| Q3 2018 | $35,577,000 | +66.4% | 3,457,402 | +8.7% | 0.00% | +100.0% |
| Q2 2018 | $21,374,000 | -21.4% | 3,180,583 | +0.5% | 0.00% | -33.3% |
| Q1 2018 | $27,192,000 | -57.4% | 3,165,566 | +3.0% | 0.00% | -57.1% |
| Q4 2017 | $63,897,000 | +42.6% | 3,071,949 | +21.2% | 0.01% | +40.0% |
| Q3 2017 | $44,801,000 | +56.7% | 2,535,414 | +0.3% | 0.01% | +25.0% |
| Q2 2017 | $28,597,000 | -11.3% | 2,528,462 | +0.4% | 0.00% | 0.0% |
| Q1 2017 | $32,258,000 | -41.5% | 2,518,198 | +0.4% | 0.00% | -42.9% |
| Q4 2016 | $55,133,000 | +22.6% | 2,507,167 | +17.8% | 0.01% | +16.7% |
| Q3 2016 | $44,980,000 | – | 2,128,719 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |